Description of Invention: Rotaviruses are recognized as the single most important etiologic agent of severe diarrhea in both developed and nondeveloped countries. This invention embodies an attenuated rotavirus as a vaccine. The claims of the invention relate to the generation of a cold-adapted virus that is not efficient in replication at normal human body temperatures and therefore may be capable of stimulating an immune response without causing illness. In a limited clinical trial, administration of a cold-adapted rotavirus vaccine to 26 adults demonstrated that the vaccine was safe, attenuated, and was capable of inducing a virus-specific serologic response.
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: changke@mail.nih.gov Phone: 301-435-5018 Fax: 301-402-0220
Description of Invention:
Rotaviruses are recognized as the single most important etiologic agent of severe diarrhea in both developed and nondeveloped countries. This invention embodies an attenuated rotavirus as a vaccine. The claims of the invention relate to the generation of a cold-adapted virus that is not efficient in replication at normal human body temperatures and therefore may be capable of stimulating an immune response without causing illness. In a limited clinical trial, administration of a cold-adapted rotavirus vaccine to 26 adults demonstrated that the vaccine was safe, attenuated, and was capable of inducing a virus-specific serologic response.
Inventors:
Yasutaka Hoshino (NIAID)
Albert Z Kapikian (NIAID)
Robert M Chanock (NIAID)
Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220
Ref No: 1192
Updated: 02/2011